VR
VREX.O
—
NASDAQ
Health Care Equipment & Supplies
Vrex.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
496,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-3,3 %
ROE
-14,9 %
Net margin
-8,3 %
Debt / equity
0,77
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$11,07
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
VREX operates in the Health Care Equipment & Supplies industry, generating revenue through medical imaging solutions, though specific product lines are not detailed in the available data.
Business. VREX operates in the Health Care Equipment & Supplies industry, generating revenue through medical imaging solutions, though specific product lines are not detailed in the available data.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target18,80
Analyst recommendations
5 analysts · consensus BuyBuy4
Hold1
Sell0
12-month price target
18,80
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
-14,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to VREX.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
VREX operates in the Health Care Equipment & Supplies industry, generating revenue through medical imaging solutions, though specific product lines are not detailed in the available data.
Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
AI synthesis
GENERATEDVREX maintains a capital structure characterized by significant leverage relative to its equity base. The company holds $145 million in cash and equivalents against $366 million in long-term debt, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio stands at 0.77, indicating moderate leverage. Liquidity is assessed as medium risk, supported by a current ratio that is not explicitly provided but implied by the balance sheet composition of $1.1 billion in total assets and $620.8 million in total liabilities. The market capitalization is approximately $466.5 million, trading at a price-to-book ratio of 0.96, suggesting the market values the company near its tangible book value.
Profitability metrics indicate the company is currently unprofitable on an operating and net basis. Operating income is negative at -$27.8 million, and net income is -$70.3 million for the latest period. This results in a negative return on equity of -14.88% and a negative return on assets of -6.35%. The gross profit is $290.5 million on revenue of $844.6 million, implying a gross margin of approximately 34.4%, which provides a buffer for operating expenses but is currently insufficient to cover them. The EV/EBITDA ratio is negative at -24.73, reflecting the lack of positive earnings before interest, taxes, depreciation, and amortization.
Segment and geographic revenue breakdowns are not provided in the available data, preventing an analysis of revenue concentration or specific market exposures. The company's activity is broadly classified under Health Care Equipment & Supplies, but without segment data, the specific drivers of the $844.6 million in revenue remain opaque in this snapshot.
Growth trajectory analysis is limited by the absence of historical period data in the input. The current revenue figure of $844.6 million serves as the baseline, but year-over-year or quarter-over-quarter trends cannot be calculated from the provided financial snapshot alone. The operating cash flow is positive at $41.7 million, which is a critical positive indicator amidst the net income loss, suggesting that core operations are generating cash despite accounting losses.
Risk assessment highlights medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which poses a refinancing or cash management risk if operating cash flows decline. The dilution risk is low, with basic and diluted shares outstanding being identical at 41.69 million, indicating no significant in-the-money options or warrants currently impacting the share count.
Recent observations include analyst estimates with a mean price target of $18.80 and a median of $18.00, suggesting a potential upside from the current market price of $11.19. The mean recommendation is 1.80, leaning towards a buy, with two strong buys and two buys recorded. News events indicate system reconciler activities for coverage closure, but no specific corporate news events such as earnings releases or strategic announcements are detailed in the observations.
Key takeaways
- VREX is currently unprofitable with a net loss of $70.3 million and negative operating income of $27.8 million.
- The company generates positive operating cash flow of $41.7 million, providing liquidity despite net losses.
- Leverage is moderate with a debt-to-equity ratio of 0.77 and negative net cash position.
- Analyst sentiment is positive with a mean price target of $18.80, implying significant upside from the current $11.19 price.
- Dilution risk is low as basic and diluted share counts are identical.
- Classification confidence is low (0.20), requiring careful interpretation of industry benchmarks.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$11,92
Market cap
$466.5M
Enterprise valueⓘ
$687.5M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
16.5x
P / Bⓘ
1.0x
P / Tangible bookⓘ
1.0x
Tangible book
$486.6M
Net cashⓘ
-$221.0M
Current ratioⓘ
—
Debt / equityⓘ
0.8
ROAⓘ
-6.3%
ROEⓘ
-14.9%
Cash conversionⓘ
-59.0%
CapEx / revenueⓘ
2.7%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships28 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries28
EX21:11a96226950cEX21:11a96226950cSubsidiarie97%
EX21:21eacfc2197dEX21:21eacfc2197dSubsidiarie97%
EX21:26a11312366dEX21:26a11312366dSubsidiarie97%
EX21:303fb9c3882cEX21:303fb9c3882cSubsidiarie97%
EX21:37a2ab2d18d1EX21:37a2ab2d18d1Subsidiarie97%
EX21:3c6a436009b1EX21:3c6a436009b1Subsidiarie97%
EX21:3ed5865a304cEX21:3ed5865a304cSubsidiarie97%
EX21:56cef9c85166EX21:56cef9c85166Subsidiarie97%
EX21:669af95404bbEX21:669af95404bbSubsidiarie97%
EX21:6ed4842b3aa0EX21:6ed4842b3aa0Subsidiarie97%
EX21:7becba3bc410EX21:7becba3bc410Subsidiarie97%
EX21:7ec9dcfdc28aEX21:7ec9dcfdc28aSubsidiarie97%
EX21:80ea58b58c02EX21:80ea58b58c02Subsidiarie97%
EX21:8444f52faa0cEX21:8444f52faa0cSubsidiarie97%
EX21:8719e2bd9bccEX21:8719e2bd9bccSubsidiarie97%
EX21:95a12ae93e9dEX21:95a12ae93e9dSubsidiarie97%
EX21:9613ae982b2fEX21:9613ae982b2fSubsidiarie97%
EX21:98f5ae821aeaEX21:98f5ae821aeaSubsidiarie97%
EX21:bbc2bc620e2fEX21:bbc2bc620e2fSubsidiarie97%
EX21:c771551f50f4EX21:c771551f50f4Subsidiarie97%
EX21:c7ce0f1c6b75EX21:c7ce0f1c6b75Subsidiarie97%
EX21:cd38d1eeddcdEX21:cd38d1eeddcdSubsidiarie97%
EX21:cd441711af96EX21:cd441711af96Subsidiarie97%
EX21:db7cc28d2cb3EX21:db7cc28d2cb3Subsidiarie97%
EX21:e585b0624c72EX21:e585b0624c72Subsidiarie97%
EX21:ed069aaa1220EX21:ed069aaa1220Subsidiarie97%
EX21:f3414773be88EX21:f3414773be88Subsidiarie97%
EX21:fd42c0d812ddEX21:fd42c0d812ddSubsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,91
Predicted surprise
+0,00
Beat probability
45 %
Analysts
5
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-08-01 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,91 |
| Revenue | —no estimate | —no estimate | 871,0M USD |
| Operating income | —no estimate | —no estimate | 80,4M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution5 analysts
Strong buy2
Buy2
Hold1
Sell0
Strong sell0
12-month price target$18,00 · Median $18,00
Low $12,00High $22,00
Operating income · consensus80,4M USD
EPS surprise
+0,4 %
reported vs consensus · beat
Revenue surprise
−3,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$16,00
Mean$18,80
Median$18,00
High$22,00
Spot$11,92
+57.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-3,3 %Below median
Net Margin-8,3 %Below median
ROE-14,9 %Below median
Capex / Rev2,7 %Above P75
D/E0,77Bottom quartile
Cash Conv-0,59Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 225 437 sh13 exercises · 21 grants12 insiders
- Director · Deferred Stock Units → Common StockAcquired 12 331grant · 2026-02-12
- Director · Deferred Stock Units → Common StockAcquired 14 947grant · 2026-02-12
- Director · Deferred Stock Units → Common StockAcquired 12 331grant · 2026-02-12
- Director · Deferred Stock Units → Common StockAcquired 12 331grant · 2026-02-12
- Director · Deferred Stock Units → Common StockAcquired 12 331grant · 2026-02-12
- Director · Deferred Stock Units → Common StockAcquired 12 331grant · 2026-02-12
- Director · Deferred Stock Units → Common StockDisposed 10 339exercise · 2026-02-09
- Director · Deferred Stock Units → Common StockDisposed 8 483exercise · 2026-02-09
- Director · Deferred Stock Units → Common StockDisposed 8 483exercise · 2026-02-09
- Director · Deferred Stock Units → Common StockDisposed 8 483exercise · 2026-02-09
- Director · Deferred Stock Units → Common StockDisposed 8 483exercise · 2026-02-09
- Director · Deferred Stock Units → Common StockDisposed 8 483exercise · 2026-02-09
- SVP and GM, Detectors · Performance Stock Units → Common StockAcquired 2 565grant · 2025-12-15
- Chief Financial Officer · Performance Stock Units → Common StockAcquired 4 515grant · 2025-12-15
- Chief Financial Officer · Performance Stock Units → Common StockAcquired 5 520grant · 2025-12-15
- SVP and GM, Detectors · Performance Stock Units → Common StockAcquired 3 134grant · 2025-12-15
- SVP and GM, X-Ray Sources · Performance Stock Units → Common StockAcquired 2 565grant · 2025-12-15
- SVP and GM, X-Ray Sources · Performance Stock Units → Common StockAcquired 3 134grant · 2025-12-15
- Director, President and CEO · Performance Stock Units → Common StockAcquired 15 394grant · 2025-12-15
- Director, President and CEO · Performance Stock Units → Common StockAcquired 18 801grant · 2025-12-15
- Chief Human Resources Officer · Performance Stock Units → Common StockAcquired 2 155grant · 2025-12-15
- Chief Human Resources Officer · Performance Stock Units → Common StockAcquired 2 633grant · 2025-12-15
- Director, President and CEO · Restricted Stock Units → Common StockDisposed 47 613exercise · 2025-12-10
- Chief Human Resources Officer · Restricted Stock Units → Common StockAcquired 21 875grant · 2025-12-10
- SVP and GM, X-Ray Sources · Restricted Stock Units → Common StockDisposed 4 664exercise · 2025-12-10
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- VAREX IMAGING CORPORATION Market data — financials · 2026-08-01
- reconciler_enqueue (reconciler) on VREX.O · 2026-08-01
- Varex Imaging Corp Market data — analyst estimates · 2026-08-01
- VREX.O HA canonical relationships · 2026-08-01
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2024-06-300,00 %$105M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2024-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$35M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$3M
- Funds · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Sunny S. SanyalPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 1 sellsnet -$50K10 insiders · last 365d
- Director · Common StockSold 4 510 @ $11,14$50K · 2026-03-20
- Director · Common StockOther 8 483 · 2026-02-09
- Director · Common StockOther 8 483 · 2026-02-09
- Director · Common StockOther 8 483 · 2026-02-09
- Director · Common StockOther 8 483 · 2026-02-09
- Director · Common StockOther 8 483 · 2026-02-09
- Director · Common StockOther 10 339 · 2026-02-09
- Director, President and CEO · Common StockOther 26 652 · 2025-12-10
- SVP and GM, X-Ray Sources · Common StockOther 4 664 · 2025-12-10
- SVP and GM, X-Ray Sources · Common StockOther 7 935 · 2025-12-10
- SVP and GM, X-Ray Sources · Common StockOther 5 526 @ $11,70$65K · 2025-12-10
- SVP and GM, Detectors · Common StockOther 4 664 · 2025-12-10
- SVP and GM, Detectors · Common StockOther 7 935 · 2025-12-10
- SVP and GM, Detectors · Common StockOther 3 636 @ $11,70$43K · 2025-12-10
- Director, President and CEO · Common StockOther 47 613 · 2025-12-10
- Director, President and CEO · Common StockOther 32 566 @ $11,70$381K · 2025-12-10
- Chief Human Resources Officer · Common StockOther 6 665 · 2025-12-10
- Chief Human Resources Officer · Common StockOther 1 923 @ $11,70$22K · 2025-12-10
Short positioning
1.2Mshares short-7.5% vs prior
3.02days to cover
52.7%short of daily vol
2.2Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
VREX.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Total assets (annual): USD 1.1BUnknown
- Shares outstanding (annual): 41.92MUnknown
- Shareholders' equity (annual): USD 476.9MUnknown
- Long-term debt (annual): USD 367.6MUnknown
- Current assets (annual): USD 633.6MUnknown
- Cash & equivalents (annual): USD 119.5MUnknown
- Total liabilities (annual): USD 607.2MUnknown
- Current liabilities (annual): USD 163MUnknown
- R&D expense (annual): USD 91.1MUnknown
- Net income (annual): USD -70.3MUnknown
- Operating income (annual): USD -27.8MUnknown
- Revenue (annual): USD 844.6MUnknown
- Gross profit (annual): USD 290.5MUnknown
- Cost of revenue (annual): USD 554.1MUnknown
- Pre-tax income (annual): USD -59.2MUnknown
- EPS (basic) (annual): USD-PER-SHARES -2Unknown
- EPS (diluted) (annual): USD-PER-SHARES -2Unknown
- Capex (annual): USD 22.9MUnknown
- Operating cash flow (annual): USD 41.7MUnknown
- Total operating expenses (annual): USD 318.3MUnknown
- Cash & equivalents (annual): USD 176MUnknown
- Shares outstanding (annual): 41.23MUnknown
- Long-term debt (annual): USD 567MUnknown
- Total assets (annual): USD 1.33BUnknown
Showing 24 of 39 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-03-20 00:00 UTCINSIDER1 insider transaction — 2026-03
2026-03-20 00:00 UTCINSIDER1 insider transaction — 2026-03
2026-03-20INSIDERKunkel Jay K. sold 4.5k sh — Director ~$50k
2026-02-12 00:00 UTCINSIDER18 insider transactions — 2026-02 12 derivative
2026-02-12 00:00 UTCINSIDER18 insider transactions — 2026-02 12 derivative
2026-02-12INSIDERBardwell Kathleen acquired 12.3k sh Deferred Stock Units — Director
2026-02-12INSIDERRosebrough Walter M Jr acquired 14.9k sh Deferred Stock Units — Director
2026-02-12INSIDERKunkel Jay K. acquired 12.3k sh Deferred Stock Units — Director
2026-02-12INSIDERTSINGOS CHRISTINE A acquired 12.3k sh Deferred Stock Units — Director
2026-02-12INSIDERGUERTIN TIMOTHY E acquired 12.3k sh Deferred Stock Units — Director
2026-02-12INSIDERChertoff Jocelyn D acquired 12.3k sh Deferred Stock Units — Director
2026-02-09INSIDERGUERTIN TIMOTHY E transacted 8.5k sh — Director
2026-02-09INSIDERChertoff Jocelyn D transacted 8.5k sh — Director
2026-02-09INSIDERKunkel Jay K. transacted 8.5k sh — Director
2026-02-09INSIDERTSINGOS CHRISTINE A transacted 8.5k sh — Director
2026-02-09INSIDERBardwell Kathleen transacted 8.5k sh — Director
2026-02-09INSIDERRosebrough Walter M Jr transacted 10.3k sh — Director
2026-02-09INSIDERGUERTIN TIMOTHY E disposed of 8.5k sh Deferred Stock Units — Director
2026-02-09INSIDERChertoff Jocelyn D disposed of 8.5k sh Deferred Stock Units — Director
2026-02-09INSIDERBardwell Kathleen disposed of 8.5k sh Deferred Stock Units — Director
2026-02-09INSIDERKunkel Jay K. disposed of 8.5k sh Deferred Stock Units — Director
2026-02-09INSIDERTSINGOS CHRISTINE A disposed of 8.5k sh Deferred Stock Units — Director
2026-02-09INSIDERRosebrough Walter M Jr disposed of 10.3k sh Deferred Stock Units — Director
2025-12-15 00:00 UTCINSIDER33 insider transactions — 2025-12 · net sell $511k 22 derivative
2025-12-15 00:00 UTCINSIDER33 insider transactions — 2025-12 · net sell $511k 22 derivative
2025-12-15INSIDERHartmann Andrew acquired 3.1k sh Performance Stock Units — SVP and GM, Detectors
2025-12-15INSIDERAranki Karen L acquired 2.6k sh Performance Stock Units — Chief Human Resources Officer
2025-12-15INSIDERAranki Karen L acquired 2.2k sh Performance Stock Units — Chief Human Resources Officer
2025-12-15INSIDERSANYAL SUNNY acquired 18.8k sh Performance Stock Units — Director, President and CEO
2025-12-15INSIDERSANYAL SUNNY acquired 15.4k sh Performance Stock Units — Director, President and CEO
2025-12-15INSIDERMaheshwari Shubham acquired 4.5k sh Performance Stock Units — Chief Financial Officer
2025-12-15INSIDERMaheshwari Shubham acquired 5.5k sh Performance Stock Units — Chief Financial Officer
Showing the 40 most recent of 59 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage